MedTrace Logo

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

NCT03698448 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2022-06-30

No results posted yet for this study

Summary

Randomized, double blind, placebo controlled study. The study has two parts:

Dose-finding part, followed by longer term follow-up (6 months)

Conditions

Interventions

DRUG

OligoG Dry powder for inhalation

10 capsules Dry Powder for Inhalation, BID

Sponsors & Collaborators

  • Imperial College London

    collaborator OTHER

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • European Cystic Fibrosis Society

    collaborator UNKNOWN

  • University Hospital of Cologne

    collaborator OTHER

  • Cystic Fibrosis Europe

    collaborator UNKNOWN

  • AlgiPharma AS

    lead INDUSTRY

Principal Investigators

  • Silke van Koningsbruggen-Rietschel, MD, PhD · University Hospital Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-10-01
Completion
2022-11-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698448 on ClinicalTrials.gov